## Edgar Filing: Fibrocell Science, Inc. - Form 4

Fibrocell Scie Form 4 June 23, 2016										
								OMB A	PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									3235-0287	
Check this if no longe subject to Section 16 Form 4 or Form 5	STATEN	<b>F CHANGES IN BENEFICIAL OWNERSHIP OF</b> <b>SECURITIES</b> Section 16(a) of the Securities Exchange Act of 1934,					Estimated burden hou response	urs per		
obligations may contin <i>See</i> Instruc 1(b).	Section 17(	(a) of the H	Public U	Jtility Ho	lding Co		of 1935 or Secti			
(Print or Type Re	esponses)									
1. Name and Address of Reporting Person <u>*</u> St.Clare Christine			2. Issuer Name <b>and</b> Ticker or Trading Symbol Fibrocell Science, Inc. [FCSC]			-	5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (I	Middle)	3. Date of Earliest Transaction				(Ché	eck all applicabl	e)	
C/O 405 EAGLEVIEW BLVD.			(Month/Day/Year) 06/22/2016				X_ Director 10% Owner Officer (give title Other (specify below) below)			
	4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>						
EXTON, PA	19341						Person		1 0	
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
	. Transaction Date Month/Day/Year)	2A. Deeme Execution I any (Month/Da	Date, if	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3,	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code v	Amount	(D) Price				
Reminder: Report	rt on a separate line	e for each cla	iss of sec	urities bene	-	-	-			
					inforr requi	nation con red to resp ays a curre	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab					sposed of, or convertible	Beneficially Owner securities)	1		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionDerivative		ansactiorDerivative Expiration Date	
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)		

	Derivative Security			(	or Dispose (D) (Instr. 3, 4 and 5)					
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 0.95	06/22/2016	А		36,000		(1)	06/22/2026	Common Stock	36,000

## **Reporting Owners**

Reporting Owner Name / Address		Relationships							
1	Director	10% Owner	Officer	Other					
St.Clare Christine C/O 405 EAGLEVIEW BLVD EXTON, PA 19341	. X								
Signatures									
/s/ Christine T. 00 St.Clare	6/23/2016								
<u>**</u> Signature of Reporting	Date								

## **Explanation of Responses:**

Person

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) With respect to all 36,000 options, these options vest 100% and become exercisable on the earlier of (x) June 22, 2017 or (y) the date of Fibrocell's 2017 Annual Meeting of Stockholders, subject to the grantee's continued service through the vesting date.

(2) The options were issued in connection with the reporting person's service to the Company as a member of its Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.